Enliven Therapeutics Inc. (ELVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enliven Therapeutics Inc. (ELVN) has a cash flow conversion efficiency ratio of -0.043x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.29 Million) by net assets ($453.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Enliven Therapeutics Inc. balance sheet independence to measure how much of total assets are equity-financed.
Enliven Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Enliven Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of Enliven Therapeutics Inc. to assess how comfortably operating cash covers total debt obligations.
Enliven Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enliven Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meitu Inc
F:M5U
|
0.013x |
|
Poco Holding Co Ltd
SHE:300811
|
0.018x |
|
Atkore International Group Inc
NYSE:ATKR
|
0.022x |
|
Beijing Ultrapower Software
SHE:300002
|
0.040x |
|
TransMedics Group Inc
NASDAQ:TMDX
|
0.050x |
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
|
-0.001x |
|
Ultragenyx
NASDAQ:RARE
|
0.860x |
|
Blackstone Mortgage Trust Inc
NYSE:BXMT
|
0.050x |
Annual Cash Flow Conversion Efficiency for Enliven Therapeutics Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Enliven Therapeutics Inc. from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see ELVN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.49 Million | $-70.30 Million | -0.153x | +35.23% |
| 2024-12-31 | $309.85 Million | $-73.19 Million | -0.236x | +5.19% |
| 2023-12-31 | $245.91 Million | $-61.27 Million | -0.249x | -159.67% |
| 2022-12-31 | $-76.83 Million | $-32.08 Million | 0.418x | +333.19% |
| 2021-12-31 | $106.86 Million | $-19.13 Million | -0.179x | -77.26% |
| 2020-12-31 | $84.44 Million | $-8.53 Million | -0.101x | +86.65% |
| 2019-12-31 | $28.92 Million | $-21.88 Million | -0.757x | +49.38% |
| 2018-12-31 | $5.87 Million | $-8.78 Million | -1.494x | -48.63% |
| 2017-12-31 | $8.74 Million | $-8.79 Million | -1.005x | -- |
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more